Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2015-08-14 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
CHANGE OF COMPANY SECRETARY
Board/Management Information Classification · 100% confidence The document is an announcement from a company listed on the Hong Kong Stock Exchange regarding a change in the company secretary. It details the resignation of the previous company secretary and the appointment of a new one, including their qualifications and experience. There is no financial data, report, or detailed presentation included. The document is short (2411 characters) and focuses solely on management change. According to the filing definitions, announcements about changes in senior management or board members fall under 'Board/Management Information' (MANG). Therefore, this document is best classified as MANG.
2015-08-14 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2015
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2015' and contains detailed unaudited condensed consolidated interim financial statements including profit or loss, financial position, cash flows, changes in equity, segment information, and notes. It references the change of financial year end date and provides comparative figures for the previous six months period. The document is about the six-month period ended 30 June 2015, which is a period shorter than a full fiscal year, and contains substantive financial data and analysis. It is prepared in accordance with HKAS 34 'Interim Financial Reporting' and reviewed by the Audit Committee. This matches the definition of an Interim / Quarterly Report (IR). The document is not a brief announcement or a certification, but a full interim financial report. Therefore, the correct classification is IR with high confidence. H1 2015
2015-08-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return for a listed issuer, Uni-Bio Science Group Limited, reporting changes in issued share capital and share buybacks. It includes detailed tables on share issues and repurchases, referencing specific listing rules of the Hong Kong Stock Exchange. The content focuses on disclosure of share capital changes and repurchase activities rather than financial performance, management discussion, or earnings. This type of document is a regulatory disclosure related to share capital changes and share buybacks, fitting the category of Transaction in Own Shares (POS). The document length is 6386 characters, which is substantive and contains actual data on share issues and repurchases, not merely an announcement or certification. Therefore, the appropriate classification is POS.
2015-08-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2015
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31 July 2015, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on changes in the company's capital structure and share issuance activities during a specific month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements as required by the exchange. This type of document fits best under 'Share Issue/Capital Change' (SHA) as it reports on share capital changes and movements in securities.
2015-08-05 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from Uni-Bio Science Group Limited regarding the scheduling of a board meeting to approve and publish the interim financial results for the six months ended 30 June 2015. It does not contain the actual interim financial results or substantive financial data, but rather informs about the upcoming approval and publication of such results. The document is short (1592 characters) and serves as a notice of the board meeting date and agenda, not the report itself. According to the 'MENU VS MEAL' rule, this type of announcement is best classified as a Report Publication Announcement (RPA).
2015-08-04 English
VOLUNTARY ANNOUNCEMENT RESULTS OF PHASE III UNI-E4 CLINICAL TRIAL
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Uni-Bio Science Group Limited regarding the results of a Phase III clinical trial for their drug Uni-E4. It contains detailed clinical trial data, including methodology, patient baseline characteristics, efficacy endpoints, safety results, and conclusions about the drug's effectiveness and safety. The document is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is a detailed announcement of clinical trial results, which is a type of material often disclosed as a voluntary announcement to inform investors and the market about significant developments. There is no indication that this is a financial report, earnings release, or management discussion. It is also not a proxy, voting result, or governance document. Given the nature of the content and the fact it is labeled as a "Voluntary Announcement" with detailed clinical trial results, the best fitting category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2015-08-03 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.